When tuberculosis comes back: Who develops recurrent tuberculosis in California?

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Pascopella, Lisa ^a   DeRiemer, Kathryn ^b   Watt, James P ^a   Flood, Jennifer M ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POPULATION RESEARCH; PREVENTIVE HEALTH SERVICE; RECURRENT DISEASE; RISK FACTOR; SPUTUM SMEAR; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNITED STATES;

ADULT; ANTITUBERCULAR AGENTS; CALIFORNIA; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PUBLIC HEALTH; PYRAZINAMIDE; RECURRENCE; RIFAMPIN; TUBERCULOSIS, PULMONARY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 80055119261     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026541     Document Type: Article

References (28)

1. Behr MA, Small PM, (1997) Molecular fingerprinting of Mycobacterium tuberculosis: how can it help the clinician? Clin Infect Dis 25: 806-810.
2. American Thoracic Society, CDC, and Infectious Diseases Society of America (2003) Treatment of Tuberculosis. MMWR 52 (RR-11): 1-77.
3. Panjabi R, Comstock GW, Golub JE, (2007) Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis 11: 828-837.
4. Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, et al. (2004) Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med 170: 1360-1366.
5. Sterling TR, Alwood K, Gachuhi R, Coggin W, Blazes D, et al. (1999) Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. Aids 13: 1899-1904.
6. Nunn AJ, Phillips PP, Mitchison DA, (2010) Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis 14: 241-242.
7. Centers for Disease Control and Prevention (2005) New CDC program for rapid genotyping of Mycobacterium tuberculosis isolates. MMWR Morb Mortal Wkly Rep 54: 47.
8. National Cancer Institute 2010. Joinpoint Regression Program. Available: http://srab.cancer.gov/joinpoint/. Accessed May 28, 2010.
9. Dobler CC, Crawford AB, Jelfs PJ, Gilbert GL, Marks GB, (2009) Recurrence of tuberculosis in a low incidence setting. Eur Respir J 33: 160-7.
10. Geiter L, eds. (2000) Ending neglect: the elimination of tuberculosis in the United States Washington, DC National Academy Press.
11. Centers for Disease Control and Prevention (1995) Essential components of a tuberculosis prevention and control program: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 44 (RR-11): 2.
12. Hsu LC, Vittinghoff E, Katz MH, Schwarcz SK, (2001) Predictors of use of highly active antiretroviral therapy (HAART) among persons with AIDS in San Francisco, 1996-1999. J Acquir Immune Defic Syndr 28: 345-350.
13. Hlavsa MC, Moonan PK, Cowan LS, Navin TR, Kammerer JS, et al. (2008) Human tuberculosis due to Mycobacterium bovis in the United States, 1995-2005. Clin Infect Dis 47: 168-175.
14. Rodwell TC, Moore M, Moser KS, Brodine SK, Strathdee SA, (2008) Tuberculosis from Mycobacterium bovis in binational communities, United States. Emerg Infect Dis 14: 909-16.
15. LoBue PA, Moser KS, (2005) Treatment of Mycobacterium bovis infected tuberculosis patients: San Diego County, California, United States, 1994-2003. Int J Tuberc Lung Dis 9: 333-8.
16. Francis J.Curry National Tuberculosis Center and California Department of Public Health (2008) Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Second Edition San Francisco, California Francis J.Curry National Tuberculosis Center.
17. Vernon A, Burman W, Benator D, Khan A, Bozeman L, (1999) Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium Lancet 353: 1843-1847.
18. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, et al. (1993) Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 328: 1137-1144.
19. Khan FA, Minion J, Pai M, Royce S, Burman W, et al. (2010) Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 50: 1288-1299.
20. Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, et al. (2007) Treatment Outcomes of Patients with HIV and Tuberculosis. Am J Respir Crit Care Med 175: 1199-206.
21. Burman WJ, Cohn DL, Rietmeijer CA, Judson FN, Sbarbaro JA, et al. (1997) Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment. Chest 111: 1168-1173.
22. Okechukwu CA, Krieger N, Chen J, Sorensen G, Li Y, et al. (2010) The association of workplace hazards and smoking in a U.S. multiethnic working-class population. Public Health Rep 125: 225-233.
23. Singh GK, Siahpush M, (2002) Ethnic-immigrant differentials in health behaviors, morbidity, and cause-specific mortality in the United States: an analysis of two national data bases. Hum Biol 74: 83-109.
24. d'Arc Lyra Batista J, de Fátima Pessoa Militão de Albuquerque M, de Alencar Ximenes RA, Rodrigues LC, (2008) Smoking increases the risk of relapse after successful tuberculosis treatment. Int J Epidemiol 37: 841-851.
25. Jee SH, Golub JE, Jo J, Park IS, Ohrr H, et al. (2009) Smoking and risk of tuberculosis incidence, mortality, and recurrence in South Korean men and women. Am J Epidemiol 170: 1478-1485.
26. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, et al. (2009) Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis 48: 179-185.
27. Slutkin G, Schecter GF, Hopewell PC, (1988) The results of 9-month isoniazid-rifampin therapy for pulmonary tuberculosis under program conditions in San Francisco. Am Rev Respir Dis 138: 1622-1624.
28. Centers for Disease Control and Prevention (2009) Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. MMWR 58: 1-198.